MXCT (MaxCyte) Tariff Resilience Score: 7/10 (As of Jun. 30, 2026)


MXCT MaxCyte Inc MXCT
58 GF Score
Price $1.25
GF Value $2.57
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Tariff Resilience Score?

MaxCyte MXCT -0.80% 58 Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus rates MXCT with a GF Score™ of 58/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 838 Medical Devices & Instruments companies, MaxCyte ranks better than 98.09% on this metric.

MaxCyte has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

MaxCyte has MaxCyte has a strong domestic market focus with limited international exposure, reducing its tariff risk. It has some import dependencies but can leverage alternative suppliers if needed.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MaxCyte might have Highly Resilient.

MaxCyte  (NAS:MXCT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MaxCyte Tariff Resilience Score Related Terms

MXCT vs RCEL, HYPR, CVRX: Tariff Resilience Score Comparison

For the Medical Devices subindustry, MaxCyte's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MaxCyte Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where MaxCyte's Tariff Resilience Score falls into.


MXCT
58GF Score
MaxCyte Inc MXCT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
MaxCyte (MXCT) has a Tariff Resilience Score of 7 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, MaxCyte ranks #16 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is MaxCyte's Tariff Resilience Score too high?
MaxCyte's current Tariff Resilience Score is 7. Based on the distribution chart, MaxCyte ranks #16 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Tariff Resilience Score compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #16 out of 838 companies for Tariff Resilience Score. This places MaxCyte in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. MaxCyte's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.25 — trading 51.6% below its estimated fair value. The current Tariff Resilience Score is 7. MaxCyte's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For MaxCyte (MXCT), the current Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.25 is trading 51.6% below its estimated GF Value™ of $2.57. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Tariff Resilience Score: 7
  • GF Value™: $2.57 vs. price of $1.25 (51.6% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
58GF Score

Get the complete analysis for MXCT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price
$2.57
GF Value